嵌合抗CD20单克隆抗体IBI301在中国CD20阳性非霍奇金淋巴瘤患者中的耐受性和药效学Ⅰ期临床试验研究
9例经治疗达客观缓解的CD20阳性B细胞非霍奇金淋巴瘤患者接受单次IBI301静脉输注,剂量递增为125、375、500 mg/m²,每组3例。共发生52例次不良事件,未发生严重不良事件及剂量限制性毒性,所有受试者CD20阳性及CD19阳性B细胞比例下降,IgG和IgM水平无明显变化。
要点
- IBI301单次给药耐受性良好,未发生严重不良事件及剂量限制性毒性。
- 常见不良事件包括WBC降低、上呼吸道感染、ANC降低、消化不良、高尿酸血症等。
- 所有受试者CD20阳性及CD19阳性B细胞比例下降,IgG和IgM水平无明显变化。
核心结论
- IBI301单次给药耐受性良好,受试者出现的不良反应均恢复,未发生严重不良事件及剂量限制性毒性事件。
- IBI301对CD20阳性B细胞有较好的清除作用。
研究设计与样本
- 剂量递增的Ⅰ期临床试验,纳入9例经治疗达客观缓解的CD20阳性B细胞非霍奇金淋巴瘤患者。
- 按剂量递增原则设125、375和500 mg/m²三个剂量组,每组3例逐组完成试验,均接受单次IBI301静脉输注。
- 125、375、500 mg/m²组IBI301的中位暴露量分别为243、690、980 mg。
- 采用流式细胞术检测外周血CD19阳性、CD20阳性B细胞比例,采用速率散射比浊法检测血清IgG、IgM水平进行药效学评价。
主要发现
- 9例受试者共发生52例次不良事件,125 mg/m²组18例次,375 mg/m²组14例次,500 mg/m²组20例次。
- 不良反应共26例次,其中22例次与试验药物可能有关,4例次可能无关,对症处理后均消失或恢复至基线水平。
- 常见不良事件包括WBC降低、上呼吸道感染、ANC降低、消化不良、高尿酸血症、感觉异常、口腔黏膜炎和头晕。
- 未出现不良事件导致的用药暂停、受试者退出或试验提前中止,未发生严重不良事件及剂量限制性毒性事件。
- 所有受试者CD20阳性、CD19阳性B细胞比例均有不同程度下降,IgG和IgM水平无明显变化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the tolerance and safety of a human-mouse chimeric anti-CD20 monoclonal antibody IBI301 in Chinese patients achieved objective response with CD20(+) B-cell non-Hodgkin's lymphoma (NHL). Methods: Nine patients with CD20(+) B-cell NHL received dose-escalating IBI301 infusions (250 mg/m(2), n=3; 375 mg/m(2), n=3; 500 mg/m(2), n=3, respectively). The data of all patients were collected for safety analyses. The median exposures of 125 mg/m(2), 375 mg/m(2), 500 mg/m(2) dose groups were 243, 690 and 980 mg, respectively. Safety and tolerability were evaluated by monitoring adverse events (AE). The ratios of CD19(+), CD20(+) B cells and the levels IgG and IgM were detected to evaluate the pharmacodynamics. Results: Totally 52 events of AE were observed, including 18 events of AE in 125 mg/m(2) group, 14 events of AE in 375 mg/m(2) group and 20 events of AE in 500 mg/m(2) group, respectively. There were 26 adverse reactions of 52 cases of AE, 22 reactions were judged to be probably related to IBI301, and 4 reactions were not probably related to IBI301, all disappeared or returned to baseline levels. Common AE in this study included decreased WBC, upper respiratory infection, decreased neutrophil count, dyspepsia, hyperuricemia, paresthesia, oral mucositis and dizziness. No patients quitted or trial discontinued. No severe AE (SAE) were reported. No dose-limiting toxicity (DLT) events were observed in the study. The ratio of CD20(+) and CD19(+) B cells decreased in all subjects. There was no significant changes of the levels of IgG and IgM. Conclusions: The single dose of IBI301 injection was well tolerated, and the AE occurred in the patients recovered. No SAE were reported, No DLT events were observed in the study. The IBI301 caused an elimination of the peripheral CD20-expressing B cells in all patients. Clinical trial registration: Chinadrugtrials, CTR20140762. 目的: 通过剂量递增的Ⅰ期临床试验,评价重组人-鼠嵌合抗CD20单克隆抗体注射液IBI301单次给药在经治疗达客观缓解的CD20(+) B细胞非霍奇金淋巴瘤患者中的耐受性、安全性及药效学特征。 方法: 纳入9例受试者,按剂量递增原则设125、375和500 mg/m(2)三个剂量组,每组3例逐组完成试验。3组受试者均接受单次IBI301静脉输注,125、375、500 mg/m(2)组IBI301的中位暴露量分别为243、690、980 mg。观察IBI301给药后不良事件(AE)发生情况。采用流式细胞术检测外周血CD19(+)、CD20(+) B细胞比例,采用速率散射比浊法检测血清IgG、IgM水平,进行药效学评价。 结果: 9例受试者发生52例次AE,包括:125 mg/m(2)组18例次,375 mg/m(2)组14例次,500 mg/m(2)组20例次。其中不良反应共26例次,22例次与试验药物可能有关,4例次可能无关;对症处理后均消失或恢复至基线水平。常见的AE包括WBC降低、上呼吸感染、ANC降低、消化不良、高尿酸血症、感觉异常、口腔黏膜炎和头晕。研究中未出现AE导致的用药暂停、受试者退出或试验提前中止,未发生严重AE(SAE)及剂量限制性毒性(DLT)事件。所有受试者CD20(+)、CD19(+) B细胞比例均有不同程度下降,而IgG和IgM水平无明显变化。 结论: IBI301耐受性良好,受试者出现的不良反应均恢复,未发生SAE及DLT事件。IBI301对CD20(+) B细胞有较好的清除作用。 临床试验注册: 药物临床试验登记与信息公示平台,CTR20140762。.
引用
- Jiang B, Qi JY, Sun MY, et al. [Tolerance and pharmacodynamics phase Ⅰ clinical trial study of chimeric anti-CD20 monoclonal antibody IBI301 in Chinese patients with CD20-positive non-Hodgkin's lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 29779330. doi:10.3760/cma.j.issn.0253-2727.2018.04.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。